Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukemia

  • In Business
  • 2019-05-16 05:43:19Z
  • By Reuters
Swiss drugmaker Roche
Swiss drugmaker Roche's logo is seen at their headquarters in Basel  

ZURICH (Reuters) - Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.

"Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care," Roche's Chief Medical Officer Sandra Horning said in a statement.

(Reporting by Brenna Hughes Neghaiwi; Editing by Michelle Martin)


More Related News

Everything You Need to Know About Marijuana Legalization 2.0
Everything You Need to Know About Marijuana Legalization 2.0

Derivative cannabis products will soon hit licensed Canadian dispensaries.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Business

Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.